RetaCalc
Protocol library
BlendNot ApprovedMixedVery Low confidenceSourced

Tesamorelin / Ipamorelin blend

A growth-hormone-axis blend not represented by the authorised tesamorelin product or by the intravenous ipamorelin clinical programme.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Formulation MathFixed-ratio blendNo validated frequency
Arithmetic check for a fixed 5 mg plus 5 mg blend

Every draw from a true 1:1 blend delivers equal milligram quantities of tesamorelin and ipamorelin

The referenced third-party page proposes unequal 2:1 component quantities, which cannot be obtained from a homogeneous 1:1 vial. No compatible combined schedule is therefore displayed.

View source

Evidence summary

A growth-hormone-axis blend not represented by the authorised tesamorelin product or by the intravenous ipamorelin clinical programme.

Protocol basis

The components have evidence in different formulations, routes and populations. No source establishes that combining them produces an equivalent or acceptable protocol.

What remains uncertain

Combined exposure, endocrine effects, formulation compatibility, long-term safety and clinical benefit are unknown.

Warnings and contraindications

No adequate controlled human study of the combined formulation was identified.
Authorised tesamorelin evidence does not validate adding ipamorelin.
Both components affect the growth-hormone axis and require clinical monitoring in studied settings.